J&J pharma sales shrink on Topamax and Risperdal competition
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has reported a 2% decline in its in pharmaceutical revenue to $5.6 billion as generics weighed on sales. Competition for its anti-epileptic Topamax (topiramate) and antipsychotic Risperdal (risperidone) continued to push pharmaceutical sales below that of its medical device business.